# Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

> **NCT05933499** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 63 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Bimagrumab
- **DRUG:** Tirzepatide
- **DIETARY_SUPPLEMENT:** Calcium/Vitamin D
- **BEHAVIORAL:** Lifestyle and nutrition counseling

## Key facts

- **NCT ID:** NCT05933499
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-05
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933499, "Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05933499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*